Catalent, Novo Nordisk and FTC
Consumer, labor groups urge FTC to block Catalent sale to Novo Nordisk - report
Five U.S. consumer groups and two big labor unions are pushing for the Federal Trade Commission to block Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT), arguing that a deal would hurt competition in weigh-loss drugs.
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent,
FTC Urged to Block Novo's Acquisition of Catalent Over Competition Concerns
Consumer groups and labor unions urged the U.S. FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, warning it may stifle competition in weight loss drugs and gene therapies. Concerns include limited manufacturing options for GLP-1 rivals.
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
Warren calls on FTC to scrutinize Novo Holdings' $16.5B Catalent buyout
As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S. Federal Trade Commission,
Concerns Mount Over Novo Holdings' Quest for Catalent
Consumer groups, labor unions, and Senator Elizabeth Warren have urged the FTC to block Novo Holdings from acquiring Catalent. Concerns center on competition in weight loss drugs and gene therapies. The $16.
Lawmaker asks FTC to probe Novo/Catalent deal
US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by Catalent, saying she is concerned it could have antitrust implications.
Consumer and labor groups urge FTC to block Catalent sale to Novo Nordisk
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.
STAT8d
Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants
U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...
Seeking Alpha7d
Sen. Elizabeth Warren wants FTC to scrutinize Novo Nordisk deal for Catalent
Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT). "I am concerned ...
FiercePharma3d
Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
BioSpace1d
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...
Consumer, labor groups urge FTC to block Catalent sale to Novo Holdings - report
Financial groups and labor unions urge FTC to block Nordisk Foundation's acquisition of Catalent, citing concerns about ...
What we learned from this week’s debates between Senator Elizabeth Warren and GOP challenger John Deaton
Massachusetts voters this week had two chances to watch candidates duke it out as they compete for the only statewide race on ...